Capecitabine: Clinical Trials

1,956 trials of Capecitabine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

769 completed, 362 unknown, 260 recruiting, 240 terminated. 1189 Phase 2, 462 Phase 3, 411 Phase 1, 47 Not applicable, 35 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21189Completed 433, Unknown 238, Terminated 168, Recruiting 156, Not yet recruiting 76, Active not recruiting 68, Withdrawn 44, Suspended 5, Enrolling by invitation 1
Phase 3462Completed 150, Unknown 93, Recruiting 79, Active not recruiting 55, Not yet recruiting 39, Terminated 37, Withdrawn 8, Suspended 1
Phase 1411Completed 214, Terminated 61, Unknown 43, Recruiting 39, Withdrawn 23, Active not recruiting 21, Not yet recruiting 9, Enrolling by invitation 1
Not applicable47Unknown 14, Completed 12, Terminated 8, Recruiting 6, Not yet recruiting 5, Enrolling by invitation 1, Withdrawn 1
Phase 435Completed 14, Not yet recruiting 6, Unknown 6, Recruiting 4, Terminated 4, Active not recruiting 1
Early Phase 15Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1, Withdrawn 1

Follow Capecitabine: new trials by email Literature Review of Capecitabine trials Research Report on Capecitabine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma
ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer
Phase 3Not yet recruitingOno Pharmaceutical Co., Ltd.6002027-02-012026-09-14
Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer
Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC)
Phase 3Not yet recruitingUNICANCER9902027-01-022026-08-04
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab - Local Advanced Rectal Cancer, PD-1 Inhibitor
Phase 3Not yet recruitingGuangdong Provincial People's Hospital1482027-01-012026-07-07
Feasibility Study of Huangqi Yangyuan Formula for Capecitabine-Induced Adverse Reactions in Advanced Colorectal Cancer
Capecitabine, Huangqi Yangyuan Formula (Chinese Herbal Decoction) - Advanced Colorectal Cancer, Capecitabine-Related Adverse Reaction
Not applicableNot yet recruitingHuanfang Fan352027-01-012026-11-03
Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma
Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Phase 2Not yet recruitingSun Yat-sen University2982026-12-012026-10-27
Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma
Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM) - Nasopharyngeal Cancinoma (NPC)
Phase 2Not yet recruitingSun Yat-sen University2142026-12-012026-10-29
A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer
Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Phase 4Not yet recruitingAstellas Pharma Global Development, Inc.502026-11-302026-09-21
Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors
Zanidatamab - Biliary Tract Cancer
Phase 2Not yet recruitingAnhui Provincial Hospital152026-11-302026-10-01
Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer
Oxaliplatin, 5-Fluorouracil, Capecitabine - Biliary Tract Cancer, Cholangiocarcinoma
Phase 3Not yet recruitingZhai Wenlong902026-11-302026-11-04
Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer
Oxaliplatin, Placebo, radiotherapy - Locally Advanced Rectal Cancer
Phase 3Not yet recruitingInnovent Biologics (Suzhou) Co. Ltd.5002026-11-252026-11-04
A Study of BON-C1393 in Adults With Advanced Solid Tumors
BON-C1393, Bevacizumab, Capecitabine - Solid Tumors, Advanced Solid Tumors
Phase 1Not yet recruitingBeOne Medicines902026-11-232026-10-29
SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3)
Short-course radiotherapy, Long-course radiation, PD-1 antibody (Sintilimab) - Early Low Rectal Cancer
Phase 3Not yet recruitingFudan University3942026-11-152026-11-12
A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)
Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms
Phase 4Not yet recruitingMerck Sharp & Dohme LLC1502026-11-062026-09-03
A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer
Short-course radiotherapy, Capecitabine, Oxaliplatin - Rectal Cancer, Radiotherapy
Phase 2Not yet recruitingTao Zhang1442026-11-012026-10-06
Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer
DCSZ11, Radiation, Capecitabine - Rectal Cancer
Phase 2Not yet recruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins302026-11-012026-10-28
RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
RC118(Dose 1) plus RC148(Dose 1), RC118(Dose 1) plus RC148(Dose 2), RC118(Dose 2) plus RC148(Dose 1) - Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2 / Phase 3Not yet recruitingRemeGen Co., Ltd.6802026-11-012026-11-13
A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients
HLX22, Trastuzumab, Capecitabine - HER2 + Breast Cancer
Phase 2Not yet recruitingShanghai Henlius Biotech902026-10-312026-09-17
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer
Phase 3RecruitingMerck Sharp & Dohme LLC4002026-10-232026-11-16
A Multicenter, Randomized, Controlled Phase III Clinical Trial on Adjuvant Intensified Therapy for Patients With Residual Disease After Neoadjuvant Treatment for Triple-negative Breast Cancer
Capecitabine and PD-1 inhibitor, PD-1 inhibitor, Capecitabine - Newly Diagnosed Triple-negative Breast Cancer
Phase 3Not yet recruitingShandong Cancer Hospital and Institute8522026-10-172026-10-09
A Prospective, Single-center, Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in Locally Advanced Rectal Cancer
Serplulimab, Bevacizumab, Oxaliplatin - Locally Advanced Rectal Cancer
Not applicableNot yet recruitingTang-Du Hospital482026-10-152026-10-13

Showing 20 of 1956. Sign in to see all of them.

Conditions studied

Breast Neoplasms (409)  ·  Colorectal Neoplasms (322)  ·  Rectal Neoplasms (237)  ·  Stomach Neoplasms (218)  ·  Pancreatic Neoplasms (139)  ·  Neoplasm Metastasis (124)  ·  Colonic Neoplasms (94)  ·  Neoplasms (90)  ·  Triple Negative Breast Neoplasms (67)  ·  Esophageal Neoplasms (57)  ·  Biliary Tract Neoplasms (43)  ·  Nasopharyngeal Carcinoma (36)  ·  Cholangiocarcinoma (35)  ·  Adenocarcinoma (34)  ·  Gallbladder Neoplasms (31)

Sponsors

Hoffmann-La Roche (91)  ·  Fudan University (76)  ·  Sun Yat-sen University (59)  ·  National Cancer Institute (NCI) (37)  ·  M.D. Anderson Cancer Center (30)  ·  Merck Sharp & Dohme LLC (26)  ·  Alliance for Clinical Trials in Oncology (22)  ·  Asan Medical Center (19)  ·  AstraZeneca (19)  ·  ImmunityBio, Inc. (18)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (17)  ·  Chinese Academy of Medical Sciences (16)  ·  UNICANCER (16)  ·  Tianjin Medical University Cancer Institute and Hospital (15)  ·  Pfizer (14)

Countries

United States (657)  ·  China (600)  ·  South Korea (173)  ·  France (171)  ·  Spain (166)  ·  Italy (161)  ·  United Kingdom (145)  ·  Germany (141)  ·  Canada (121)  ·  Taiwan (99)  ·  Australia (96)  ·  Japan (88)  ·  Belgium (87)  ·  Brazil (77)  ·  Poland (74)

Top investigators

Yoon-Koo Kang, MD, PhD (7)  ·  Binghe Xu (6)  ·  Christopher H. Crane, MD (6)  ·  Lin Shen, MD (6)  ·  Michele Reni, MD (6)  ·  Norman Wolmark, MD (6)

Results publications

PMID 34037241, PMID 35623069, PMID 36306483, PMID 15496622, PMID 40341124, PMID 22226517, PMID 39863139, PMID 41121239, PMID 15383798, PMID 17042060, PMID 17175450, PMID 18669454, PMID 19269519, PMID 19906561, PMID 20728210, PMID 21128114, PMID 21596621, PMID 21937232, PMID 22067400, PMID 24472478, PMID 24495589, PMID 26156652, PMID 26187751, PMID 29234923, PMID 29508247, PMID 29804905, PMID 33093337, PMID 33439695, PMID 33792646, PMID 34515993, PMID 36135045, PMID 37037952, PMID 37310167, PMID 37499870, PMID 37957132, PMID 38564700, PMID 39024777, PMID 39047732, PMID 40117530, PMID 40373876, PMID 40657894, PMID 41324998, PMID 42371751, PMID 10623705, PMID 10918161, PMID 10944647, PMID 11248153, PMID 11919232, PMID 11919233, PMID 12065558

NIH funding

2023 (28), 2008 (17), 2018 (16), U10CA032102 (13), 2016 (12), 2025 (12), 2014 (10), 2015 (9), U10CA180820 (9), 2019 (8), 2005 (7), U10CA180868 (7), 2009 (6), 2017 (6), U10CA180821 (5)